8-K: Onconetix Amends Labcorp Deal for Proclarix Validation Study

Onconetix's subsidiary, Proteomedix, amended its license agreement with Labcorp to initiate a new validation study for Proclarix, with Onconetix funding up to $300,000.

Summary

• On December 6, 2025, Onconetix, Inc.'s wholly-owned subsidiary, Proteomedix AG, entered into an amendment to its license agreement with Laboratory Corporation of America Holdings (Labcorp).
• The amendment establishes a new validation study for Proclarix, titled "Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: A Prospective U.S.-Based Multi-Center Validation Study of Proclarix" (the PRIME Study).
• Labcorp will conduct the PRIME Study and will not be required to pay royalties or milestone payments for using the Proclarix risk calculator during the study.
• Onconetix will compensate Labcorp with milestone-based payments up to an aggregate of $300,000 for conducting the PRIME Study.
• Onconetix will also bear all associated costs and expenses for the study, including providing necessary reagents and consumables.
• Milestone payments, described as "mid-five figure," will be made upon enrollment of additional batches of subjects, commencing on the PRIME Study's effective date.
• If the final milestone tier is not reached, Onconetix must pay Labcorp a fixed amount per subject enrolled beyond the last paid milestone tier.
• Labcorp is required to provide Onconetix with the results of each clinical study upon completion, but Onconetix may not use or disclose these results to third parties without Labcorp's prior written consent.

Sentiment

Score: 6

Explanation: The agreement to conduct a new validation study is a positive step for Proclarix's commercialization potential, but it comes with a direct financial cost to Onconetix and limitations on data usage, balancing the overall sentiment.

Positives

• Initiation of the PRIME Study could further validate Proclarix, potentially expanding its market acceptance and commercialization.
• Labcorp's commitment to conduct the study leverages their expertise and resources.
• The study focuses on a "multi-ethnic cohort," which could broaden the applicability and clinical utility of Proclarix in the U.S. market.

Negatives

• Onconetix is obligated to pay Labcorp up to $300,000 for conducting the study, plus all associated costs and expenses (reagents, consumables), representing a direct financial outlay.
• Labcorp is exempt from paying royalties or milestone payments for the use of the risk calculator during the PRIME Study, potentially delaying revenue generation from this specific use.
• Onconetix cannot use or disclose the study results to third parties without Labcorp's prior written consent, which could limit independent marketing or research efforts.

Risks

• The PRIME Study may not yield positive or statistically significant results, which could negatively impact the commercial prospects of Proclarix.
• Onconetix is incurring direct costs for the study (up to $300,000 plus consumables), and there is no guarantee of a return on this investment.
• Reliance on Labcorp for study execution and data disclosure introduces dependency and potential limitations on Onconetix's control over the study's narrative and dissemination.
• The redacted financial details (specific milestone amounts, per-subject payment) prevent a full understanding of the financial commitment if the study is discontinued or progresses differently than expected.

Future Outlook

The amendment indicates a strategic focus on further validating Proclarix through the PRIME Study, aiming to strengthen its position in the U.S. market for prostate cancer risk identification, particularly within a multi-ethnic cohort. The successful completion and positive results of this study are crucial for future commercialization efforts.

Management Comments

• Karina M. Fedasz signed the 8-K as Interim Chief Executive Officer and Interim Chief Financial Officer for Onconetix, Inc.
• Beat Rheiner, PhD, CEO of Proteomedix AG, and Thomas Meier, PhD, Chairman of Proteomedix AG, signed the amendment.
• Marcia T. Eisenberg, PhD, CSO and SrVP of Labcorp, signed the amendment.

Industry Context

This agreement highlights the ongoing trend in the diagnostics industry towards rigorous clinical validation, especially for novel biomarkers and risk assessment tools like Proclarix. Collaborations with large diagnostic service providers like Labcorp are common for smaller biotech companies to gain market access and credibility, particularly in the U.S. market. The focus on a multi-ethnic cohort addresses an important aspect of health equity and broader applicability in diverse populations.

Comparison to Industry Standards

• The collaboration with a major diagnostic player like Labcorp for a validation study is a standard industry practice for emerging diagnostic companies seeking to commercialize novel tests, similar to partnerships seen with companies like Exact Sciences (Cologuard) or Grail (Galleri) for large-scale clinical trials and market penetration.
• The structure of milestone payments for study enrollment is a common funding mechanism in clinical research agreements, aligning incentives for study progression.
• The focus on a multi-ethnic cohort for prostate cancer risk identification aligns with increasing industry and regulatory emphasis on diverse clinical trial populations to ensure broader applicability and reduce health disparities, a practice adopted by leading research institutions and pharmaceutical companies.

Stakeholder Impact

• Shareholders: Incurrence of study costs (up to $300,000 plus expenses) could impact short-term financials, but successful study results could enhance long-term value by validating Proclarix.
• Customers (Healthcare Providers/Patients): Potential for a more robustly validated prostate cancer risk identification tool, especially for diverse populations, if the PRIME Study is successful.
• Employees: Continued development and validation of a key product could provide stability and future growth opportunities.

Next Steps

• Labcorp will use commercially reasonable efforts to complete the PRIME Study.
• Onconetix will make milestone-based payments to Labcorp as subjects are enrolled in the PRIME Study.
• Labcorp will provide Onconetix with the results of each clinical study upon completion.

Key Dates

Recommendation

The initiation of the PRIME Study is a necessary and potentially positive step for Proclarix's long-term commercial viability, demonstrating continued development and partnership with a leading diagnostic provider. However, the immediate financial outlay for Onconetix (up to $300,000 plus expenses) and the lack of immediate revenue generation from this specific use, coupled with restrictions on data disclosure, suggest a 'hold' position. Investors should await the study results and further clarity on commercialization pathways before making a more definitive investment decision.

Keywords

Onconetix, Proteomedix, Labcorp, Proclarix, PRIME Study, License Agreement, Clinical Validation, Prostate Cancer, SEC Filing, 8-K, Biotechnology, Diagnostics